

allogeneic bone marrow transplants for 10 days before transplantation, on the day of transplantation and for 10 days after transplantation were examined retrospectively in terms of interaction. Two paid softwares and two free softwares were used to examine interactions. The obtained data were analyzed with Microsoft Excel program. **Results:** A total of 3805 interactions were observed in the 21-day period in 50 patients who underwent allogeneic stem cell transplantation, and these interactions occurred with the repetition of 1017 interactions in different patients. For the same period in 50 autologous stem cell transplant patients, 2906 interactions were detected, and this number occurred with 725 different interactions seen in different patients. It has been understood that anti-infectives cause serious interaction load. **Conclusion:** Hematopoietic stem cell transplantation is a period in which prophylactic or anti-infective treatment for the detected microorganism is applied intensively. Interactions of anti-infectives with each other and with other drugs in the treatment regimen are frequently encountered during the transport process. Interactions should be identified and their clinical significance should be demonstrated. It should be handled with the partnership of physician-clinical pharmacist.

<https://doi.org/10.1016/j.htct.2021.10.1053>

PP 44

EVALUATION OF COMMON INTERACTIONS INCLUDING ANTI-INFECTIVE DRUGS IN PATIENTS UNDERWENT AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION

Ayşe Gunay¹, Ali Unal², Eren Demirpolat¹

¹ Erciyes University, Faculty of Pharmacy, Clinical Pharmacy Department

² Erciyes University, Faculty of Medicine, Hematology Department

Objective: Hematopoietic stem cell transplantation is a challenging process involving polypharmacy. Drug-drug interactions are common due to the large number of drugs used in patients, and anti-infectives are frequently involved in interactions due to their widespread use. **Methodology:** In our study, the drugs used by a total of 100 patients with 50 autologous and 50 allogeneic bone marrow transplants for 10 days before transplantation, on the day of transplantation and for 10 days after transplantation were examined retrospectively in terms of interaction. Two paid softwares and two free softwares were used to examine interactions. The obtained data were analyzed with Microsoft Excel program. **Results:** 1017 different interactions were detected in patients with allogeneic bone marrow transplantation and 725 different interactions in patients with autologous bone marrow transplantation. It was observed that 342 interactions were common in the two transplant types. Interactions involving anti-infectives have been studied and the data showed antifungals, antibacterials and antivirals cause significant interaction load. Some interactions were found to be dependent on the transplant process. **Conclusion:** Allogeneic bone marrow transplantation and autologous bone marrow transplantation

are challenging processes in which intensive drug therapy is applied. Knowing the interactions that are common to both types of transplantation and the interactions involving anti-infectives specific to a certain period of the transplantation process allows the process to be managed effectively. It is important to manage interactions in physician-clinical pharmacist collaboration

<https://doi.org/10.1016/j.htct.2021.10.1054>

TRANSFUSION MEDICINE AND APHERESIS

PP 45

THERAPEUTIC PLASMA EXCHANGE IN PATIENTS WITH NEUROLOGICAL DISEASES: A 9-YEAR, SINGLE-CENTER EXPERIENCE

Merih Reis Aras¹, Mehlika Panpalli Ates², Murat Albayrak¹, Hacer Berna Afacan Ozturk¹, Abdulkirim Yildiz³, Fatma Yilmaz¹, Bugra Saglam¹, Selim Selcuk Comoglu²

¹ University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Hematology Department

² University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Neurology Department

³ Ministry of Health Hitit University Erol Olcok Training and Research Hospital, Hematology Department

Objective: Therapeutic plasma exchange (TPE), is based on the removal of pathogenic substrates from plasma with replacement fluid. TPE is being used in the treatment of many neurological diseases, especially Myasthenia Gravis (MG) and Guillain Barre Syndrome (GBS). The aim of this study is to analyse the efficacy and safety of TPE experience in neurological disorders. **Methodology:** We reviewed the medical records of all 59 patients who received a total of 267 therapeutic cycles between 2012 and 2021 in our tertiary care university hospital. Respond assesment was evaluated with Medical Research Council (MRC) scoring system. Neutrophil count, lymphocyte count and neutrophil/lymphocyte ratio was recorded before any treatment and 7 days after the last plasmapheresis cycle. **Results:** Of the 59 patients, 30 (50.8%) were male and 29 (49.2%) were female. Of these patients 44.1% were diagnosed with MG, 27.3% with GBS, %8.5 with Multiple Sclerosis (MS). The median number of TPE sessions per patient was 5 [1-7]. 33.9 % of patients had at least one complication that hypotension was the most seen (%22). Overall response rate was %76.3. MRC score was significantly higher in the group with response than the group without symptom regression ($p < 0.05$). **Conclusion:** TPE is a safe and an effective treatment option in neurological diseases. TPE related side effects/complications were generally mild to moderate and manageable. Performing the TPE response evaluation with the MRC scoring system was beneficial for the reliability of the efficacy as a concrete finding.

<https://doi.org/10.1016/j.htct.2021.10.1055>